title: Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts.
abstract: The development of post-transplantation coronary graft disease (CGD) is a major cause of late morbidity and mortality. Recent reports have suggested that CGD is a type of chronic vascular rejection, possibly enhanced by cofactors such as concurrent CMV infection and hyperlipidemia. It remains controversial whether established CGD can be improved by modifications in immunosuppressive therapy. The purpose of this study was to examine whether CsA could reverse or halt the progression of CGD after it was already established. Lewis to Fisher (F-344) heterotopic heart allografts develop CGD resembling human disease. Group 1 (n = 29) had no CsA therapy for chronic rat CMV (RCMV) infection in recipients for 8 weeks before transplant. Group 2 (n = 17) had chronic RCMV infection along with CsA therapy from days 15 to 28 post-transplant. Allografts were killed at 2 and 4 weeks and 90 days post-transplantation. In group 1, leukocyte adhesion to arterial endothelium and intimal hyperplasia were well established at 2 weeks and progressed to stenotic, proliferative arterial lesions at 4 weeks. In group 2, CsA therapy was effective in significantly reversing histologic parameters of vascular rejection such as leukocyte adhesion, intimal proliferation, and periarterial edema at 4 weeks. By 90 days, however, arterial pathology was as severe as in group 1. In conclusion, these results support the hypothesis that CGD is a form of chronic vascular rejection, and once established, can be significantly modified by CsA therapy. These effects are not permanent, and progressive CGD recurs after CsA therapy is discontinued.
authors.affiliation: Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205.
authors.forename: N
authors.initials: N
authors.lastname: Handa
authors.forename: M
authors.initials: M
authors.lastname: Hatanaka
authors.forename: W A
authors.initials: WA
authors.lastname: Baumgartner
authors.forename: B A
authors.initials: BA
authors.lastname: Reitz
authors.forename: G
authors.initials: G
authors.lastname: Sandford
authors.forename: A H
authors.initials: AH
authors.lastname: Esa
authors.forename: A
authors.initials: A
authors.lastname: Herskowitz
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control*; D016572:Cyclosporine / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D016572:Cyclosporine